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A B S T R A C T  
Background: Oral isotretinoin is the recommended treatment for acne vulgaris, a skin disease especially common in teenagers 
and adolescents. This study was designed to compare the efficacy and safety of low dose with high dose isotretinoin in severe acne 
vulgaris patients. 
Material and Methods: This randomized controlled trial included 110 patients with a clinical diagnosis of acne vulgaris. They 
were divided into two groups. Both groups were matched for age (mean 18.2±3.7 vs 17.6±3.2 years), weight (mean 58±10.2 vs 
60.7±9.3 Kg), gender and disease duration (3±1.1 vs 3±1.0 years).  Group A received low dose oral isotretinoin (20 mg/day) while 
group B received standard high dose regimen (1mg/kg/day). All patients were followed up for 16 weeks to assess efficacy 
(assessment of complete remission) and safety (mucocutaneous side effects). All calculations were performed using SPSS v. 16 
with p value <0.05 considered as statistically significant. 
Results: There was no statistically significant difference in efficacy. However, significantly fewer mucocutaneous side effects were 
reported in group A (80%) as compared to group B (100%). This safety profile spectrum was observed across all pre-defined 
subsets i.e chielitis (78.1% vs 98.2%), dry skin (69.1% vs 92.7%), dry mouth (47.2% vs 72.7%) and facial rash (12.7% vs 30.9%). 
Conclusion: In patients with severe acne vulgaris, efficacy (complete remission) of low dose oral isotretinoin is almost equal to 
conventional high dose regimen but it is statistically superior in terms of safety (mucocutaneous side effects). 
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I n t r o d u c t i o n  
 
Acne vulgaris (AV) is the most common skin disease 
worldwide characterized by chronic inflammation of 
pilosebaceous units which, if left untreated, may lead to 
detrimental physical and psychological effects.1 The 
disease is more common in younger age groups, ranging 
from 70%2 in teenagers to as high as 90% in 
adolescents.3 Currently, oral and topical antibiotics and 
retinoids represent the most widely accepted conventional 
therapies for acne.  Isotretinoin (13-cis retinoic acid) 
represents the single most important pharmacological 
advancement in acne therapeutics. Its conventional dose 
is 0.5-1 mg/kg/day in single or divided doses.  The current 
practices follow a cumulative oral isotretinoin dose of 120-
150 mg/kg of body weight in severe acne, over a period of 
16-24 weeks. However, the common dose-dependent 
side-effects have compelled the researchers to look for 
substitute protocols.4 Some recent studies have proposed 
a safer and almost as efficacious regimen with lower 
doses of oral isotretinoin, while others have failed to show 
any significant alternative.4-6 Sardana et al and Agarwal et 
al reported comparative efficacy of 69% vs. 96% (low 
dose isotretinoin vs. high dose isotretinoin) in terms of 
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complete remission of acne vulgaris over a period of 
sixteen weeks.5,6  
Similarly, low dose to high dose mucocutaneous side 
effects at 89% vs. 100% have been documented.6 
However, such protocols have not been advocated in the 
guidelines so far due to the paucity of published data for 
an optimal dosage regimen. Some of the physicians are 
thus opting for institution-based practices of high dose, 
low dose, pulsed and alternate day isotretinoin, while 
others have failed to show any dosage regimens. The 
pursuit of a robust regimen becomes all the more 
important in our setting considering the unique acne 
dynamics of South Asian population7 as well as the 
financially constrained healthcare system. This study aims 
to find the efficacy and safety of high and low doses of 
oral isotretinoin in severe acne vulgaris patients 
presenting in our tertiary care hospital set-up. 
 
M a t e r i a l  a n d  M e t h o d s  
This randomized controlled trial was conducted at 
Dermatology out-patient department of Pakistan Institute 
of Medical Sciences (PIMS), Islamabad from 10th March, 
2013 to 9th January, 2014. Sample size was computed 
using WHO calculator taking 5% level of significance with 
95% power of the test.6 Calculated sample size was 55 in 
each group. Both male and female patients with severe 
acne vulgaris, more than 12 years of age, presenting at 
the out-patient of Dermatology unit were included. 
Pregnant and breast-feeding, married females desiring to 
have pregnancy within 6 months after initiation of therapy 
were excluded.  
 
Patients having Hypersensitivity to retinoids, patients with 
baseline triglyceride levels > 400 mg/dL and/or total 
cholesterol > 300 mg/dL, ALT > 60/uL and/or AST > 80/Ul 
were also excluded from the study. Drug induced acne i.e. 
acne in patients on isoniazid, phenytoin, lithium, 
azathioprine, cyclosporine and those already on anti-acne 
treatment were not included in the study. Permission was 
taken from the hospital’s ethical committee. Informed 
written consent was taken from the enrolled patients and 
confidentiality was maintained throughout the study. 
Detailed history and clinical examination of all severe 
acne vulgaris patients was done at first hospital visit to 
assess for the suitability for enrollment in the study. FDA 
global acne scale was applied to assess the baseline 
severity of disease. Liver function tests (LFTs) and lipid 
profile were obtained. 
 
All enrolled patients were equally divided into Group A 
(low dose isotretinoin) and Group B (high dose 
isotretinoin) by lottery method. Single blinded protocol 
was followed by concealing any information about their 
allotment group from the patients. Group A was 
prescribed oral isotretinoin at a dose of 20 mg once a day 
while Group B was given 1 mg/kg/day in divided doses. 
All patients were asked to swallow the capsule with meal 
to avoid gastrointestinal side effects. Furthermore, all 
patients were advised to apply topical 1% clindamycin gel 
twice daily as per the standard acne guidelines. Strict 
compliance with the treatment protocol was advocated 
throughout the study period. Patients were followed for 
sixteen weeks at monthly intervals. LFTs and lipid profile 
were checked on each follow up visit. 
 
Therapy was discontinued if blood tests showed AST > 
80/ul or ALT > 60/ul or Cholesterol > 300mg/dl or 
Triglycerides > 400mg/dl. Treatment protocol was termed 
efficacious if there was complete resolution of acne 
vulgaris features on clinical examination at 16 weeks of 
therapy. Patients were asked to report in clinic if they 
experienced any mucocutaneous side effects as already 
described. Patients not presenting for follow up were 
contacted on telephone and early clinic visit was 
emphasized. Subjects withdrawing consent and those 
who discontinued therapy by themselves for more than a 
week were addressed as "drop out" and excluded in the 
outcome analysis, same as for patients lost to follow up.  
 
All statistical calculations were performed using SPSS 
version 16 (Statistical Package for the Social Sciences, 
SPSS Inc. USA). Mean and standard deviation were 
calculated for age, weight and duration of the disease. 
Frequency and percentages were calculated for 
categorical variables such as gender, efficacy and safety. 
Effect modifiers like site and duration of disease, age, 
gender was controlled by stratification. Independent 
sample t test was applied to test baseline characteristics. 
Chi square test was used to compare efficacy and safety 
outcomes. P value of less than 0.05 was considered 
statistically significant. 
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R e s u l t s  
A total of 110 patients were included in the analysis (55 in 
each group). Table I shows the baseline characteristics of 
the study sample. In group A, females were more while in 
group B, there was male dominancy. In group A, median 
age was 17 years with an age range 12-27 years. In 
group B, median age was 17 years with a range of 12-25 
years. Subjects of group A had median weight of 57 kg 
(range 36-85 Kg) while in group B, median weight was 60 
Kg (range was 37-82 Kg). No statistically significant 
difference was noted in both groups as far as age 
(p=0.38), weight (p=0.15), gender (p=0.18) and duration 
of disease (p=1.0) were considered. Table II shows 
efficacy and safety outcomes of both groups after 16 
weeks follow-up. Although complete remission of acne 
was observed in 52 patients (94.5%) of group A and all 
patients of group B (100%), the difference was not 
statistically significant (p= 0.07). However, significantly 
fewer mucocutaneous side effects were reported in low 
dose isotretinoin group (80%) as compared to 
conventional high dose isotretinoin group (100%) (Table 
II) (RRR 20%, p 0.0004) (Figure 1).  
 
 
Figure 1: Safety outcome at 16 weeks 
 
This safety profile spectrum was observed across all pre-
defined subsets (Table II) i.e. cheilitis (RRR 20%, p 
0.001), dry skin (RRR 25%, p 0.002), dry mouth (RRR 
34%, p 0.006) and rash (RRR 60%, p 0.02) (Figure 1). An 
excellent (100%) follow up in both groups was achieved at 
16 weeks and no major side effect leading to 
discontinuation of study drug was reported. 
 
D i s c u s s i o n  
Acne vulgaris (AV) is an extremely prevalent skin 
condition1,2 affecting majority of teenagers to a certain 
degree at some point. The onset of AV is usually shortly 
before or during early adolescence; however, some cases 
start in latter childhood with the subset of preadolescent 
acne defined within the ages of 7 and 11 years.8 The 
impact on the quality of life of young people is highly 
significant. It has a greater negative effect on the 
emotions and social functioning of teenagers than 
diseases like asthma and epilepsy.3 It is often associated 
with anxiety, depression and unemployment3. The impact 
of the condition is often difficult to determine clinically, but 
Table I: Baseline characteristics of patients (n= 110) 
Variables Group A  
(low dose) 
(n=55) 
Group B  
(high dose) 
(n=55) 
Age (years); mean + SD 18.2 ± 3.7 17.6 ± 3.2 
Male; n (%) 27 (49) 34 (61) 
Female; n (%) 28 (51) 21 (39) 
Weight (Kg); mean + SD 58.0 ± 10.2 60.7 ± 9.3 
Duration of disease 
(Years); mean + SD 
3.0 ± 1.1 3.0 ± 1.0 
Table II:  Efficacy and Safety Outcomes of Isotretinoin at 16 weeks (n=110) 
 
Efficacy outcome 
Group A (n=55) 
n (%) 
Group B 
(n=55) 
n (%) 
Odds ratio 
(OR) 
Relative Risk 
Reduction 
(RRR %) 
95% 
Confidence 
interval (CI) 
p value 
Complete remission 52 (94.5) 55 (100) 0.48  0.40-0.59 0.07 
Safety outcome       
Mucocutaneous side effects 44 (80) 55 (100) 0.44 20 0.35-0.55 <0.001 
Cheilitis 43 (78.1) 54 (98.2) 0.06 20 0.008-0.53 0.001 
Dry skin 38 (69.1) 51 (92.7) 0.17 25 0.05-0.56 0.002 
Dry mouth 26 (47.2) 40 (72.7) 0.33 34 0.15-0.74 0.006 
Rash 7 (12.7) 17 (30.9) 0.32 60 0.12-0.86 0.02 
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one can assume that almost all acne patients will 
experience this impact to some degree. Medical treatment 
can make a very big difference, often clearing the 
condition completely, or bringing about significant 
improvement in those who do not experience complete 
clearance. Isotretinoin is regarded as a useful therapeutic 
advance in the management of acne. It has been 
recommended for the treatment of severe nodulocystic 
acne in the doses of 1-2 mg/day.5,6  
 
While using this treatment protocol, the incidence of side-
effects is quite high and requires regular monitoring 
including a watch on the serum lipid profile.9 In this study, 
we have tested the notion that compared to conventional 
high dose, lower dose of oral isotretinoin is superior in 
terms of complete remission as well as carries a much 
better safety profile in patients of severe AV. Although no 
statistically significant superiority in efficacy is established 
in this regard, it cannot be ascertained at present whether 
lower doses are actually inferior to conventional (high) 
dosing in terms of complete remission of acne. However, 
in our study, lower doses have shown significant 
superiority by limiting mucocutaneous side effects. This 
superiority is dictated throughout the spectrum of pre-
defined side effects i.e. cheilitis, dry skin, dry mouth and 
rash. Another interesting finding is the possible 
association of efficacy to the duration of disease. 
 
All three cases of treatment failure had acne for more 
than four years. However, this study was not designed or 
powered to assess such parameter. To decrease the 
incidence of side-effects and to make the therapy protocol 
simpler, the lower dose regimen has been tried by various 
authors before.5,6,10 However, unlike our study, most of 
these studies targeted mild to moderate acne population. 
Sardana et al5 studied lower doses of oral isotretinoin in 
mild to moderate acne and reported efficacy of up to 90% 
with statistically significant non-inferiority to conventional 
high dose regimen. Long-term relapse rate was also 
same across both groups. Similarly, Agerwal et al 6 
reported better efficacy (69% vs 96%) and safety 
outcomes (89% vs 100%) in favor of lower doses of oral 
isotretinoin across different stages of acne. Each of these 
studies had one or more major limitations, including 
retrospective nature of the data collection, statistically 
insignificant number of patients and selection of low acne 
load patients with mild to moderate class. This study may 
be influenced by several limitations as well. Only patients 
with severe acne load were addressed. It was left up to 
the discretion of patients which Isotretinoin preparations 
to buy from available brands. Furthermore, relevance on 
patient interview or clinician impression may be 
insufficient to detect poor adherence to medications. 
Despite these limitations, this study provides new insights 
into the possibility of finding a more robust, efficacious, 
much safer regimen of oral isotretinoin than the one in 
practice for severe acne vulgaris. 
 
C o n c l u s i o n  
Low dose oral isotretinoin, over a period of 16 weeks, is 
not superior to conventional high dose regimen in terms of 
complete remission of severe acne vulgaris. However, it 
has a statistically significant safety profile accounting for 
fewer mucocutaneous side effects as compared to latter. 
Future studies should be designed to prospectively test 
such unorthodox regimens for the overall cost 
effectiveness, and to assess for both superiority as well 
as non-inferiority compared to high dose regimen. 
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